These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

431 related articles for article (PubMed ID: 10659396)

  • 1. Antiemetics for cancer chemotherapy-induced nausea and vomiting. A review of agents in development.
    Rizk AN; Hesketh PJ
    Drugs R D; 1999 Oct; 2(4):229-35. PubMed ID: 10659396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    Support Care Cancer; 2001 Jul; 9(5):350-4. PubMed ID: 11497388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal use of antiemetics in the outpatient setting.
    Grunberg SM
    Oncology (Williston Park); 2002 Oct; 16(10):1401-7; discussion 1407-8, 1412. PubMed ID: 12435208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug treatment of chemotherapy-induced delayed emesis.
    Tavorath R; Hesketh PJ
    Drugs; 1996 Nov; 52(5):639-48. PubMed ID: 9118814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM
    J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.
    Trigg ME; Higa GM
    J Oncol Pharm Pract; 2010 Dec; 16(4):233-44. PubMed ID: 20085961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment options for chemotherapy-induced nausea and vomiting.
    Hesketh PJ
    Support Care Cancer; 2004 Aug; 12(8):550-4. PubMed ID: 15232725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-emetic therapy in cancer chemotherapy: current status.
    Herrstedt J; Dombernowsky P
    Basic Clin Pharmacol Toxicol; 2007 Sep; 101(3):143-50. PubMed ID: 17697032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
    Navari RM
    Paediatr Drugs; 2017 Jun; 19(3):213-222. PubMed ID: 28447301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
    Goodman M
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
    Aapro M; Blower P
    Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
    de Wit R; Aapro M; Blower PR
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):231-8. PubMed ID: 15838653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?
    Schwartzberg LS
    Oncology (Williston Park); 2007 Jul; 21(8):946-53; discussion 954, 959, 962 passim. PubMed ID: 17715696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the pathobiology of chemotherapy-induced nausea and vomiting. Providing a basis for therapeutic progress.
    Hesketh PJ
    Oncology (Williston Park); 2004 Sep; 18(10 Suppl 6):9-14. PubMed ID: 15510975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New perspectives in antiemetic treatment.
    Herrstedt J
    Support Care Cancer; 1996 Nov; 4(6):416-9. PubMed ID: 8961471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.